These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9821299)

  • 1. Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27.
    Asanuma F; Yamada Y; Kawamura E; Lee K; Kobayashi H; Yamada T; Suzuki T; Kubota T
    Folia Microbiol (Praha); 1998; 43(5):473-4. PubMed ID: 9821299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of taxanes in treatment of breast cancer].
    Gorbunova VA; Besova NS
    Vopr Onkol; 2004; 50(4):492-500. PubMed ID: 15605777
    [No Abstract]   [Full Text] [Related]  

  • 3. Docetaxel and epirubicin plus G-CSF as mobilizing treatment to support high-dose chemotherapy in breast cancer.
    De Rosa L; Lalle M; Perillo A; Pierelli L; Salerno MG; Cortesi E; Martelli O; Pandolfi A; Amodeo R; Marzetti L; Mancuso S; Scambia G
    Anticancer Res; 2001; 21(2B):1367-70. PubMed ID: 11396215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
    Fujimoto S; Chikazawa H
    Jpn J Cancer Res; 1998 Dec; 89(12):1343-51. PubMed ID: 10081496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer.
    Lück HJ; Du Bois A; Thomssen C; Lisboa B; Untch M; Köhler G; Hecker D
    Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):34-7. PubMed ID: 9144689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Greater antitumor efficacy of paclitaxel administered before epirubicin in a mouse mammary carcinoma.
    Cividalli A; Cruciani G; Livdi E; Cordelli E; Eletti B; Tirindelli Danesi D
    J Cancer Res Clin Oncol; 1998; 124(5):236-44. PubMed ID: 9645453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: a dose escalation study.
    Bonneterre J; Tubiana-Hulin M; Catimel G
    Oncology; 2004; 66(3):185-91. PubMed ID: 15218308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antitumor activity of UFT and docetaxel on human breast carcinoma xenografts].
    Yamada T; Yamada Y; Asanuma F; Kawamura E; Suzuki T
    Gan To Kagaku Ryoho; 2000 Oct; 27(11):1725-30. PubMed ID: 11057324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin.
    Lück HJ; Thomssen C; Du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):36-9. PubMed ID: 9516602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey.
    Paridaens R
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):3-6. PubMed ID: 9865704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel plus epirubicin in advanced breast cancer.
    Conte PF; Gennari A; Salvadori B; Pazzagli C; Bengala C
    Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):40-4. PubMed ID: 9516603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
    Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.
    Hunz M; Jetter A; Warm M; Pantke E; Tuscher M; Hempel G; Jaehde U; Untch M; Kurbacher C; Fuhr U
    Clin Pharmacol Ther; 2007 May; 81(5):659-68. PubMed ID: 17301739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines.
    Budman DR; Calabro A
    Breast Cancer Res Treat; 2002 Jul; 74(1):41-6. PubMed ID: 12150451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance gene expression and chemotherapy sensitivity detection in Chinese women with different molecular subtypes of breast cancer.
    Zhao J; Zhang H; Lei T; Liu J; Zhang S; Wu N; Sun B; Wang M
    Cancer Biol Med; 2020 Nov; 17(4):1014-1025. PubMed ID: 33299650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of giant advanced ulcerative breast cancer managed with epirubicin and cyclophosphamide followed by weekly paclitaxel].
    Moriya T; Fukatsu K; Ueda S; Iwaya K; Osaki A; Yamamoto J
    Gan To Kagaku Ryoho; 2010 May; 37(5):907-10. PubMed ID: 20495326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
    Miglietta L; Marenghi C; Nizzo R; Foglia G; Ragni N; Boccardo F
    Oncology; 2001; 60(2):116-22. PubMed ID: 11244325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.